<!DOCTYPE html>
<html lang="en"><head>
<script src="Lecture1_files/libs/clipboard/clipboard.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tabby.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/popper.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="Lecture1_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="Lecture1_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/all.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/latex-fontsize.css" rel="stylesheet">
<script src="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.js"></script>
<link href="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/glightbox/lightbox.css" rel="stylesheet"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.4.552">

  <title>lecture1</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/theme/quarto.css">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/font-awesome/css/all.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/style.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    padding-bottom: 0.5rem;
    margin-bottom: 0;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">


<section id="lecture-3-β-lactams-and-β-lactamases" class="slide level2" data-background-image="images/flemming1.png" data-background-opacity="0.2">
<h2>Lecture 3: β-lactams and β-lactamases</h2>
<p><br> <br> <br> <br> <br></p>
<p><strong>Russell E. Lewis</strong> <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua</p>
<p><a href="images/unipd.png" class="lightbox" data-gallery="quarto-lightbox-gallery-1"><img data-src="images/unipd.png" class="absolute" style="top: 550px; left: 950px; width: 100px; height: 100px; "></a></p>
<p><br> <i class="fa-solid fa-envelope fa-1x" aria-label="envelope"></i> russelledward.lewis@unipd.it <br> <i class="fa-brands fa-github fa-1x" aria-label="github"></i> <a href="https://github.com/Russlewisbo/ESCMID_2022_talk">https://github.com/Russlewisbo</a></p>
</section>
<section id="outline" class="slide level2">
<h2>Outline</h2>
<p><br></p>
<ul>
<li>Antibiotic classes</li>
<li>Mechanism of action</li>
<li>Pharmacokinetics/Pharmacodynamics</li>
<li>Resistance</li>
<li>Role in therapy</li>
</ul>
</section>
<section id="discovery-of-penicillin" class="slide level2">
<h2>Discovery of penicillin</h2>
<p><br> <br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/pcn2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-2"><img data-src="images/pcn2.png"></a></p>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="https://i.makeagif.com/media/7-05-2015/V0HT6G.gif" class="lightbox" data-gallery="quarto-lightbox-gallery-3" data-glightbox="description: .lightbox-desc-3" title="Sir Alexander Fleming in his laboratory, Pathé Films"><img data-src="https://i.makeagif.com/media/7-05-2015/V0HT6G.gif" alt="Sir Alexander Fleming in his laboratory, Pathé Films"></a></p>
<figcaption>Sir Alexander Fleming in his laboratory, Pathé Films</figcaption>
</figure>
</div>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="fleming_1929">(<a href="#/references" role="doc-biblioref" onclick="">Fleming, 1929</a>)</span></p>
</div></aside></section>
<section id="natural-penicillins" class="slide level2">
<h2>Natural penicillins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/natural%20penicillins.png" class="lightbox" data-gallery="quarto-lightbox-gallery-4"><img data-src="images/natural%20penicillins.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</section>
<section id="isoxazolyl-penicillins" class="slide level2 smaller">
<h2>Isoxazolyl penicillins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/isoxyl%20penicillins.png" class="lightbox" data-gallery="quarto-lightbox-gallery-5"><img data-src="images/isoxyl%20penicillins.png" class="quarto-figure quarto-figure-center" width="700"></a></p>
</figure>
</div>
</section>
<section id="aminopenicillins" class="slide level2 smaller">
<h2>Aminopenicillins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/amino.png" class="lightbox" data-gallery="quarto-lightbox-gallery-6"><img data-src="images/amino.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</section>
<section id="extended-spectrum-penicillins" class="slide level2 smaller">
<h2>Extended-spectrum penicillins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/extended%20spectrum%20penicillins.png" class="lightbox" data-gallery="quarto-lightbox-gallery-7"><img data-src="images/extended%20spectrum%20penicillins.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>
</section>
<section id="mechanism-of-action" class="slide level2">
<h2>Mechanism of action</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="https://i.makeagif.com/media/4-07-2017/l7_PRO.gif" class="lightbox" data-gallery="quarto-lightbox-gallery-8" data-glightbox="description: .lightbox-desc-8" title="Inhibition of transpeptidase (PBP)"><img data-src="https://i.makeagif.com/media/4-07-2017/l7_PRO.gif" alt="Inhibition of transpeptidase (PBP)"></a></p>
<figcaption>Inhibition of transpeptidase (PBP)</figcaption>
</figure>
</div>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="https://i.makeagif.com/media/10-05-2017/e3c7kf.gif" class="lightbox" data-gallery="quarto-lightbox-gallery-9" data-glightbox="description: .lightbox-desc-9" title="Lysis of growing bacterial cells"><img data-src="https://i.makeagif.com/media/10-05-2017/e3c7kf.gif" alt="Lysis of growing bacterial cells"></a></p>
<figcaption>Lysis of growing bacterial cells</figcaption>
</figure>
</div>
</div>
</div>
<p><br></p>
</section>
<section id="spectrum-of-activity" class="slide level2 smaller">
<h2>Spectrum of activity</h2>
<p><br> <br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/pcnspextrum.png" class="lightbox" data-gallery="quarto-lightbox-gallery-10"><img data-src="images/pcnspextrum.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>
<ul>
<li><p><strong>Good:</strong> <em>Treponema pallidum</em>, most streptococci, including <em>Streptococcus pneumoniae</em></p></li>
<li><p><strong>Moderate:</strong> Enterococci</p></li>
<li><p><strong>Poor:</strong> Almost everything else (penicillinases, β-lactamases)</p></li>
</ul>

<aside><div>
<p>Source: Sanford Guide Web</p>
<p>++ Preferred + activity; ± limited utility; 0 not recommended</p>
</div></aside></section>
<section id="pharmacodynamics-of-β-lactam-antibiotics" class="slide level2 smaller" data-background-image="images/killrate.png" data-background-opacity="0.1">
<h2>Pharmacodynamics of <strong>β-lactam</strong> antibiotics</h2>
<p><br> <br></p>
<ul>
<li><strong>β-lactam antibiotics exhibit relatively concentration-independent killing</strong>
<ul>
<li><p>The rate of killing reaches its maximum very quickly as the drug concentration increases from the MIC to 4–6 times the MIC and falls precipitously when the drug concentration decline below the MIC</p></li>
<li><p>Related to mechanism of action: acylation of their targets, the β-lactam-binding proteins</p></li>
<li><p>Once maximal acylation is achieved, the killing rates cannot increase any further. This explains why the killing rates for β-lactam drugs are maximal at a low multiple of the MIC</p></li>
</ul></li>
<li><span style="border-radius: 0.2rem; padding: 0 0.2rem 0 0.2rem;background-color: #ffe536;"><strong>% Time &gt; MIC is the pharmacodynamically linked variable</strong></span></li>
<li><strong>Clinical implications:</strong> Activity of β-lactams with short half-lives is optimized by prolonging drug exposure above the MIC (extended or continuous infusion)</li>
</ul>

<aside><div>
<p><span class="citation" data-cites="drusano2004">(<a href="#/references" role="doc-biblioref" onclick="">Drusano, 2004</a>)</span></p>
</div></aside></section>
<section id="pharmacokinetics-natural-penicillins" class="slide level2 smaller">
<h2>Pharmacokinetics: Natural penicillins</h2>
<p><br> <br></p>
<table>
<colgroup>
<col style="width: 15%">
<col style="width: 84%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Penicillin VK (oral); bioavailibility 60-73% <br> Penicillin G (IV) <br>Benzathine penicillin (IM) <br></td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.35 L/kg</p></li>
<li><p>65% protein bound</p></li>
<li><p>500% bile:serum</p></li>
<li><p>5-10% CSF:blood (therapeutic for some pathogens)</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½ 0.5 hr</p></li>
<li><p>Substrate of OAT transporters</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Renal 100%, impaired by probenicid</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical doses</strong></td>
<td><p>(Pen VK) 250-500 mg TID-QID before meals and at bedtime</p>
<p>(Low dose) 600,000-1.2 MU IM/day</p>
<p>(High dose) Penicillin G: &gt; 20 MU IV daily</p></td>
</tr>
</tbody>
</table>

<aside><div>
<p>Source: Sanford Guide</p>
</div></aside></section>
<section id="cns-toxicities" class="slide level2 smaller">
<h2>CNS Toxicities</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/seizues.png" class="lightbox" data-gallery="quarto-lightbox-gallery-11"><img data-src="images/seizues.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>
<p>The β-lactam ring structure is an important determinant of the epileptogenic properties. Evidence suggests that substitutions occurring at the 7-aminocephalosporanic or 6- aminopenicillanic acid (6-APA) positions may lead to alterations in epileptogenic activity. The thiazolidine ring and side chain length also plays a role in determining the pro-convulsive effects of β-lactams</p>

<aside><div>
<p><span class="citation" data-cites="wanleenuwat2020">(<a href="#/references" role="doc-biblioref" onclick="">Wanleenuwat et al., 2020</a>)</span></p>
</div></aside></section>
<section id="other-adverse-effects" class="slide level2">
<h2>Other adverse effects</h2>
<p><br></p>
<ul>
<li><p>Most serious reaction is immediate IgE-mediated anaphylaxis; incidence only 0.05% but 5-10% fatal. Other IgE-mediated reactions: urticaria, angioedema, laryngeal edema, bronchospasm</p>
<ul>
<li>Morbilliform rash after 72 hours is not IgE-mediated and not serious</li>
</ul></li>
<li><p>Serious late allergic reactions: Coombs-positive hemolytic anemia, neutropenia, thrombocytopenia, serum sickness, interstitial nephritis, hepatitis, eosinophilia, drug fever</p></li>
</ul>
</section>
<section id="clinical-role" class="slide level2">
<h2>Clinical role</h2>
<p><br></p>
<ul>
<li><p>Poor empiric choice for most infections because of resistance</p></li>
<li><p>Drug of choice for syphilis particularly neurosyphilis (ceftriaxone use is increasing)</p></li>
</ul>
<p><br></p>
</section>
<section id="pharmacokinetics-anti-staphylococcal-penicillins" class="slide level2 smaller">
<h2>Pharmacokinetics: <br>Anti-staphylococcal penicillins</h2>
<p><br> <br></p>
<table>
<colgroup>
<col style="width: 10%">
<col style="width: 89%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Dicloxacillin (oral- bioavailibility 60-73%) <br> Methicillin (IV-not used); <br> Flucloxacillin (oral and IV, bioavailibility 50%) <br> Nafcillin (IV)<br>Oxacillin (IV) <br></td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.1-0.5 L/kg</p></li>
<li><p>&gt;95% protein bound</p></li>
<li><p>Limited data on CNS penetration</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td>Not metabolised but some drugs can induce CYP P450 (dicloxacillin, flucloxacillin)</td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Biliary with some renal (no dosing adjustment for renal impairment)</td>
</tr>
<tr class="odd">
<td><strong>Typical doses</strong></td>
<td>125-500 every 6h (oral); 1-2 gram IV every 4-6h</td>
</tr>
</tbody>
</table>
</section>
<section id="adverse-effects" class="slide level2">
<h2>Adverse Effects</h2>
<p><br></p>
<ul>
<li><p>Local phlebitis, (<em>problematic with frequent IV dosing),</em></p></li>
<li><p>Fever, rash (4%), anaphylaxis (rare)</p></li>
<li><p>+ Coombs (rare), neutropenia (prolonged treatment), eosinophilia (22%), thrombocytopenia</p></li>
<li><p><em>C. difficile</em> colitis (rare)</p></li>
<li><p>Increased LFTs, headache (rare), confusion (rare),</p></li>
<li><p>Acute interstitial nephritis (less than methicillin)</p></li>
<li><p>Hepatic dysfunction-more problematic with doses ≥12 gm/day (oxacillin &gt; nafcillin)</p>
<ul>
<li>LFTs usually increase 2–24 days after start of treatment, reversible</li>
</ul></li>
</ul>
</section>
<section id="drug-interactions" class="slide level2 smaller">
<h2>Drug interactions</h2>
<p><br></p>
<ul>
<li><p>Flucloxacillin (also dicloxacillin?) activates the pregnane X receptor (PXR), which can induce the expression of CYP450 and UGT enzymes, and P-gP transporters</p>
<p><a href="images/clipboard-1261899633.png" class="lightbox" data-gallery="quarto-lightbox-gallery-12"><img data-src="images/clipboard-1261899633.png"></a></p></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="wei2016">(<a href="#/references" role="doc-biblioref" onclick="">Wei et al., 2016</a>)</span></p>
</div></aside></section>
<section id="mechanisms-of-resistance" class="slide level2 smaller">
<h2>Mechanisms of Resistance</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/resistance%20mechanisms.png" class="lightbox" data-gallery="quarto-lightbox-gallery-13"><img data-src="images/resistance%20mechanisms.png" class="quarto-figure quarto-figure-center" width="700"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="deoliveira2020">(<a href="#/references" role="doc-biblioref" onclick="">De Oliveira et al., 2020</a>)</span></p>
<ul>
<li><p>Methicillin resistance encoded by <em>mecA, mecC, which code for low-affinity PBP2a and PBP2c</em></p></li>
<li><p>Genes can be detected by latex agglutination test of PCR (nasal swabs)</p></li>
</ul>
</div></aside></section>
<section id="current-resistance-epidemiology" class="slide level2 smaller">
<h2>Current resistance epidemiology</h2>
<iframe width="1200" height="900" src="https://resistancemap.onehealthtrust.org/AntibioticResistance.php" title="Resistance Map">
</iframe>
</section>
<section id="clinical-role-1" class="slide level2">
<h2>Clinical role</h2>
<p><br></p>
<ul>
<li><p>Infections caused by MSSA, such as endocarditis, bloodstream infections, and skin and soft-tissue infections</p></li>
<li><p>β-lactams kill staphylococci more quickly than vancomycin, so patients with MSSA infections who lack serious beta-lactam allergies should be switched to beta-lactams, such as antistaphylococcal penicillins or first-generation cephalosporins</p></li>
</ul>
<p><br></p>
</section>
<section id="spectrum-aminopenicillins" class="slide level2 smaller">
<h2>Spectrum: Aminopenicillins</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/pcnspextrum.png" class="lightbox" data-gallery="quarto-lightbox-gallery-14"><img data-src="images/pcnspextrum.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p>Source: Sanford Guide Web</p>
<p>++ Preferred + activity; ± limited utility; 0 not recommended</p>
</div></aside></section>
<section id="ambler-classification-of-beta-lactamases" class="slide level2 smaller">
<h2>Ambler classification of beta-lactamases</h2>
<p><br></p>
<p>Clavulanic acid and sulbactam are suicide inhibitors of Ambler class A enzymes</p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/Ambler.png" class="lightbox" data-gallery="quarto-lightbox-gallery-15"><img data-src="images/Ambler.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="noster2021">(<a href="#/references" role="doc-biblioref" onclick="">Noster et al., 2021</a>)</span></p>
</div></aside></section>
<section id="mechanisms-of-resistance-to-beta-lactamase-inhibitors" class="slide level2">
<h2>Mechanisms of resistance to <br>beta-lactamase inhibitors</h2>
<p><br></p>
<ul>
<li><p><strong>Intrinsic (e.g., 1st-Gen BLIs don’t work against AmpC or Carbapenemases)</strong></p></li>
<li><p><strong>BLI-R beta lactamases (point mutation —&gt; less binding of 1st-gen BLIs)</strong></p>
<ul>
<li><p>Narrow-spectrum: TEM-30, SHV-10</p></li>
<li><p>ESBL: TEM-50</p></li>
</ul></li>
<li><p><strong>Hyperproduction of beta-lactamase (more common)</strong></p>
<ul>
<li>E.g. ESBL E.coli, or Klebsiella SHV-1</li>
</ul></li>
</ul>
</section>
<section id="amoxicillin-clavulanate-resistance" class="slide level2">
<h2>Amoxicillin-clavulanate resistance</h2>
<iframe width="1200" height="900" src="https://resistancemap.onehealthtrust.org/AntibioticResistance.php" title="Resistance Map">
</iframe>
</section>
<section id="pharmacokinetics-aminopenicillins" class="slide level2 smaller">
<h2>Pharmacokinetics: Aminopenicillins</h2>
<table>
<colgroup>
<col style="width: 15%">
<col style="width: 84%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Ampicillin (IV) <br> Ampicillin-sulbactam (IV) <br> Amoxicillin (oral, 80% bioavail.) <br> Amoxicillin-clavulanate (oral 80% bioavail., IV)</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.25-0.36 L/kg</p></li>
<li><p>18-22% protein bound</p></li>
<li><p>500% bile:serum</p></li>
<li><p>5-10% CSF:blood (therapeutic for some pathogens)</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½ 1.2-1.5 hr</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>ampicillin, amoxicillin, sulbactam- renal, clavulanate-hepatic, bile and renal</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical adult doses</strong></td>
<td><ul>
<li><p>Ampicillin 1-2 gram IV q4-6h<br></p></li>
<li><p>Ampicillin-sulbactam : 3 gram IV q6h; up to 9 gram IV over 4hrs q8h for <em>Acinetobacter</em> spp. VAP<br></p></li>
<li><p>Amoxicillin 500-1000 mg TID; ER tab 775 mg once daily; <br></p></li>
<li><p>Amoxicillin-clavulanate 500-1000 mg ( 125-200 clav) twice daily <br></p></li>
<li><p>Amoxicillin-clavulanate 1000/200 IV q8h IV</p></li>
</ul></td>
</tr>
</tbody>
</table>

<aside><div>
<p>Source: Sanford Guide</p>
</div></aside></section>
<section id="beta-lactamase-inhibitors" class="slide level2 smaller">
<h2>Beta-lactamase inhibitors</h2>
<div class="smaller">
<table style="width:99%;">
<colgroup>
<col style="width: 7%">
<col style="width: 27%">
<col style="width: 47%">
<col style="width: 16%">
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Clavulanic acid</th>
<th>Sulbactam</th>
<th>Tazobactam</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Chemical structure</strong></td>
<td>Clavam, similar to penicillin nucleus</td>
<td>Penicillanic acid sulfone</td>
<td>Penicillanic acid sulfone</td>
</tr>
<tr class="even">
<td><strong>Origin</strong></td>
<td>Isolated from <em>Streptomyces clavuligerus</em> in the 1970s</td>
<td>Developed 1978 (synthetic)</td>
<td>Developed 1980 (synthetic)</td>
</tr>
<tr class="odd">
<td><strong>Drugs</strong></td>
<td>Amoxicillin: Co-amoxiclav (Augmentin) 1988 Ticarcillin: Ticarcillin-clavulanate (Timentin)</td>
<td>Ampicillin/Sulbactam (Unasyn)</td>
<td>Piperacillin/Tazobactam Ceftolozane/Tazobactam</td>
</tr>
<tr class="even">
<td><strong>Active against</strong></td>
<td><p>Penicillinases / narrow-spectrum beta lactamases</p>
<p>ESBL , OXA-53</p></td>
<td><ul>
<li><p>Penicillinases / narrow-spectrum beta lactamases</p></li>
<li><p>ESBL</p></li>
<li><p>Intrinsically active against Acinetobacter baumannii (directly inhibits PBP1 &amp; PBP3). - Also against N.gonorrhoea + B.fragilis but not used clinically.</p></li>
</ul></td>
<td><ul>
<li><p>Penicillinases / narrow-spectrum beta lactamases</p></li>
<li><p>ESBL • OXA-2,32</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Not active against</strong></td>
<td>AmpC Cephalosporinases Carbapenemases (KPC, OXA-48, MBLs)</td>
<td><p>AmpC Cephalosporinases</p>
<p>Carbapenemases</p></td>
<td>AmpC Cephalosporinases Carbapenemases</td>
</tr>
</tbody>
</table>
</div>
<p><br></p>
<ul>
<li><p>These are structurally similar to penicillin, and target class A including ESBL (but not KPC), but have no activity against class B (MBL), C (AmpC) or D (OXA) beta lactamases.</p></li>
<li><p>Act as ‘suicide inhibitors’ —&gt; covalently bind serine residue in binding site (many molecules of BLI per beta-lactamase required to produce inhibition)</p></li>
</ul>
</section>
<section id="amoxicillinclavulanate-dosing" class="slide level2" data-background-image="images/amox.png" data-background-opacity="0.1">
<h2>Amoxicillin/clavulanate dosing</h2>
<p><br></p>
<ul>
<li>Plasma amoxicillin exposures are generally linear and proportional at doses up to 750 mg, after which absorption becomes saturated and bioavailability decreases from approximately 60% at 750 mg to approximately 55% at 875 mg or 1000 mg and to approximately 35% at 2000 mg
<ul>
<li><strong>Standard dose</strong>: (oral, e.g., UTI): (0.5 g amoxicillin + 0.125 g clavulanic acid) x TID</li>
<li><strong>UTI dose:</strong> (0.5 g amoxicillin + 0.125 g clavulanic acid) TID</li>
<li><strong>High dose:</strong> (0.875 g amoxicillin + 0.125 g clavulanic acid) TID</li>
<li><strong>High dose IV:</strong> (2 g amoxicillin + 0.2 g clavulanic acid) q8h</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="huttner2020">(<a href="#/references" role="doc-biblioref" onclick="">Huttner et al., 2020</a>)</span> and EUCAST Clinical Breakpoint Tables v. 14.0</p>
</div></aside></section>
<section id="empiric-considerations-for-amoxclav-use" class="slide level2">
<h2>Empiric considerations for amox/clav use</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/huttner.png" class="lightbox" data-gallery="quarto-lightbox-gallery-16"><img data-src="images/huttner.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="huttner2020">(<a href="#/references" role="doc-biblioref" onclick="">Huttner et al., 2020</a>)</span></p>
</div></aside></section>
<section id="adverse-effects-1" class="slide level2 smaller">
<h2>Adverse effects</h2>
<p><br></p>
<ul>
<li><p>Persons with infectious mononucleosis, i.e., Epstein-Barr virus (EBV), are likely to develop rash. It is not a permanent allergy</p></li>
<li><p>In patients with true Amoxicillin allergy, increased risk of cross allergenicity with oral cephalosporins that have an identical R1 side chain: i.e., cefadroxil and cefprozil</p></li>
<li><p>Hepatotoxicity linked to clavulanic acid. Amoxicillin-clavulanate is most common cause,13-23%, of drug-induced cholestatic liver injury</p>
<ul>
<li><p>Onset delayed several days after end of antibiotic therapy</p></li>
<li><p>Genetic predisposition. Usually mild; rare liver failure</p></li>
</ul></li>
<li><p>Treatment stopped due to adverse affects (2-4.4%)</p>
<ul>
<li>fever, rash (3%), anaphylaxis (rare), neutropenia, eosinophilia, thrombocytopenia (rare), nausea/vomiting (3%), diarrhea (9%), <em>C. difficile</em> colitis, increased LFTs, headache, seizures (rare)</li>
</ul></li>
<li><p>With BID regimen, less clavulanate &amp; less diarrhea</p></li>
<li><p>In patients with immediate allergic reaction to amoxicillin-clavulanate, 1/3 are due to the clavulanate. Diarrhea due to clavulanate</p></li>
</ul>
</section>
<section id="what-is-the-clinical-role-of-aminopenicllins--β-lactamase-inhibitor" class="slide level2">
<h2>What is the clinical role of aminopenicllins <br> +/-β lactamase inhibitor?</h2>
<p><br></p>
<ul>
<li><strong>Ampicillin is a drug of choice for susceptible enterococci</strong>
<ul>
<li>Enterococcus faecalis is almost always susceptible; Enterococcus faecium is usually resistant</li>
</ul></li>
<li>These drugs are often listed as alternative regimens for urinary tract infections (UTIs) in pregnant women because they are pregnancy category B and eliminated renally</li>
<li><strong>Amoxicillin/clavulanate is used for upper and lower respiratory tract infections when beta-lactamase–producing organisms are found or suspected</strong>
<ul>
<li>It can also be useful for UTIs when resistance to other drugs is seen, but it should not be given for a short 3-day course, as with fluoroquinolones or TMP/SMX</li>
</ul></li>
</ul>
</section>
<section id="extended-spectrum-anti-pseudomonal-penicillins" class="slide level2 smaller">
<h2>Extended-spectrum <br>(anti-pseudomonal) penicillins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/extended%20spectrum%20penicillins.png" class="lightbox" data-gallery="quarto-lightbox-gallery-17"><img data-src="images/extended%20spectrum%20penicillins.png" class="quarto-figure quarto-figure-center" width="500"></a></p>
</figure>
</div>
</section>
<section id="spectrum-of-piperacillin-tazobactam" class="slide level2">
<h2>Spectrum of piperacillin-tazobactam</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/pcnspextrum.png" class="lightbox" data-gallery="quarto-lightbox-gallery-18"><img data-src="images/pcnspextrum.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p>Source: Sanford Guide Web</p>
<p>++ Preferred + activity; ± limited utility; 0 not recommended</p>
</div></aside></section>
<section id="ambler-classification-of-beta-lactamases-1" class="slide level2 smaller">
<h2>Ambler classification of beta-lactamases</h2>
<p><br></p>
<p>Should piperacillin-tazobactam be used for severe ESBL infections?</p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/Ambler.png" class="lightbox" data-gallery="quarto-lightbox-gallery-19"><img data-src="images/Ambler.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="noster2021">(<a href="#/references" role="doc-biblioref" onclick="">Noster et al., 2021</a>)</span></p>
</div></aside></section>
<section id="merino-trial" class="slide level2">
<h2>MERINO trial</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/MERINO1.png" class="lightbox" data-gallery="quarto-lightbox-gallery-20"><img data-src="images/MERINO1.png"></a></p>
</div><div class="column" style="width:50%;">
<p><a href="images/MERINO2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-21"><img data-src="images/MERINO2.png"></a></p>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="harris2018">(<a href="#/references" role="doc-biblioref" onclick="">Harris et al., 2018</a>)</span></p>
</div></aside></section>
<section id="pharmacokinetics-of-piperacillin-tazobactam" class="slide level2 smaller">
<h2>Pharmacokinetics of piperacillin-tazobactam</h2>
<p><br></p>
<table>
<colgroup>
<col style="width: 15%">
<col style="width: 84%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>IV only</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.4 L/kg</p></li>
<li><p>16% piperacillin; 48% tazobactam</p></li>
<li><p>&gt;100% bile:serum</p></li>
<li><p>CSF:blood pentration- limited data</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½ 1 hr</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Renal, may interfere with SeCr excretion</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical adult doses</strong></td>
<td><ul>
<li><p><strong>Typical dosing:</strong> Piperacillin/tazobactam 3.375 gram IV q6h of 4.5 gram IV q8h (severe infections)</p></li>
<li><p><strong><em>P. aeruginosa</em></strong> <strong>pneumonia</strong>: 3.375 g IV q4h or 4.5 gram IV q6h combined with antipseudomnal aminoglycosides or fluoroquinolone</p></li>
<li><p><strong>Prolonged infusion:</strong> 4.5 gram IV over 30 minutes followed by 3.375 gram IV infused over 4 hours</p></li>
</ul></td>
</tr>
</tbody>
</table>
</section>
<section id="bling-iii" class="slide level2">
<h2>BLING III</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/bling1.png" class="lightbox" data-gallery="quarto-lightbox-gallery-22"><img data-src="images/bling1.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="dulhunty2024">(<a href="#/references" role="doc-biblioref" onclick="">Dulhunty et al., 2024</a>)</span></p>
</div></aside></section>
<section id="bling-iii--enrolment-criteria" class="slide level2">
<h2>BLING III- Enrolment criteria</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/bling2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-23"><img data-src="images/bling2.png" class="quarto-figure quarto-figure-center" width="700"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="dulhunty2024">(<a href="#/references" role="doc-biblioref" onclick="">Dulhunty et al., 2024</a>)</span></p>
</div></aside></section>
<section id="bling-iii-results" class="slide level2">
<h2>BLING III results</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/bling3.png" class="lightbox" data-gallery="quarto-lightbox-gallery-24"><img data-src="images/bling3.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p>Effect size= 2% reduction. NNT of 50 patients to prevent 1 death</p>
<p><span class="citation" data-cites="dulhunty2024">(<a href="#/references" role="doc-biblioref" onclick="">Dulhunty et al., 2024</a>)</span></p>
</div></aside></section>
<section id="bling-iii-1" class="slide level2">
<h2>BLING III</h2>
<p><br> <br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/bling4.png" class="lightbox" data-gallery="quarto-lightbox-gallery-25"><img data-src="images/bling4.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>
</section>
<section id="meta-analysis-the-bigger-picture" class="slide level2 smaller">
<h2>Meta-analysis: The bigger picture</h2>
<p><a href="images/BLING_meta.png" class="lightbox" data-gallery="quarto-lightbox-gallery-26"><img data-src="images/BLING_meta.png"></a></p>

<aside><div>
<p><span class="citation" data-cites="abdul-aziz2024">(<a href="#/references" role="doc-biblioref" onclick="">Abdul-Aziz et al., 2024</a>)</span></p>
</div></aside></section>
<section id="adverse-effects-2" class="slide level2 smaller">
<h2>Adverse effects</h2>
<p><br> <br></p>
<ul>
<li>Platelet dysfunction can occur in patients with renal failure, due to impaired platelet aggregation</li>
<li>Drug-induced immune thrombocytopenia</li>
<li>Allergic reactions can occur with any of the beta-lactam antibiotics.</li>
<li>Treatment stopped due to adverse effects: (3.2%):
<ul>
<li>Local phlebitis (1%), fever (2%), rash (4%) - Serum sickness, positive Coombs, neutropenia, eosinophilia, thrombocytopenia, increased PT/PTT, - nausea/vomiting (7%), diarrhea (11%), C. difficile colitis, - Increased LFTs, increased BUN/Creatinine, headache (8%), confusion (rare), seizures (rare). - Hypokalemia</li>
</ul></li>
</ul>
</section>
<section id="increased-risk-of-renal-failure-with-vancomycin" class="slide level2" data-background-image="images/kidney-1.svg" data-background-opacity="0.2">
<h2>Increased risk of renal failure with vancomycin?</h2>
<p><br></p>
<ul>
<li><strong>Does combining vancomycin with piperacillin-tazobactam amplify the risk of vancomycin nephrotoxicity?</strong>
<ul>
<li>Many observational retrospective studies have reported an increased risk of acute kidney injury in association with the combination of piperacillin-tazobactam and vancomycin as compared to either drug alone</li>
<li>No reported increased risk of AKI if vancomycin is combined with cefepime or meropenem</li>
</ul></li>
<li><strong>The attributable nephrotoxicity due to vancomycin due in part to multiple con founders</strong>
<ul>
<li>Animal studies suggest “injury” is a consequence of competetion for tubular secretion of creatinine</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="pais2020">(<a href="#/references" role="doc-biblioref" onclick="">Pais et al., 2020</a>)</span></p>
</div></aside></section>
<section id="monobactams" class="slide level2 smaller">
<h2>Monobactams</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/aztreonam.png" class="lightbox" data-gallery="quarto-lightbox-gallery-27"><img data-src="images/aztreonam.png" class="quarto-figure quarto-figure-center" width="400"></a></p>
</figure>
</div>
</section>
<section id="aztreonam-spectrum-of-activity" class="slide level2">
<h2>Aztreonam: Spectrum of activity</h2>
<p><br> <br></p>
<p><a href="images/aztreonam_spectrum.png" class="lightbox" data-gallery="quarto-lightbox-gallery-28"><img data-src="images/aztreonam_spectrum.png"></a></p>
<ul>
<li>Only gram-negative with some <em>P. aeruginosa</em> coverage</li>
<li>No useful activity against gram-positive bacteria or anaerobes</li>
<li>However, degraded by Class A and C beta-lactamases</li>
</ul>
</section>
<section id="safe-drug-for-penicillin-allergic-patients" class="slide level2">
<h2>Safe drug for penicillin allergic patients?</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:40%;">
<div class="quarto-figure quarto-figure-right">
<figure>
<p><a href="images/sidechains.png" class="lightbox" data-gallery="quarto-lightbox-gallery-29"><img data-src="images/sidechains.png" class="quarto-figure quarto-figure-right" width="250"></a></p>
</figure>
</div>
</div><div class="column" style="width:60%;">
<p>Exception: Aztreonam has R1 side-chain identical to that of ceftazidime and cefiderocol, so in those with allergy to that side-chain, there may be cross-sensitivity</p>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="castells.etal_2019">(<a href="#/references" role="doc-biblioref" onclick="">Castells et al., 2019</a>)</span></p>
</div></aside></section>
<section id="coming-soon" class="slide level2 smaller">
<h2>Coming soon…</h2>
<p><br></p>
<center>
Aztreonam-avibactam!
</center>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/comingsoon.png" class="lightbox" data-gallery="quarto-lightbox-gallery-30"><img data-src="images/comingsoon.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>
<ul>
<li>Why combine?- Aztreonam is not hydrolyzed by metallo-lactamases (class B), but is degraded by some Ambler class A and C β-lactamases</li>
<li>Avibactam is an inhibitor of serine β-lactamases (Class A and C) and some Class D (OXA-48)</li>
<li>The combination restores activity against carbapenase-producing organisms</li>
<li>Avoids use of ceftazime-avibactam + aztreonam</li>
</ul>
</section>
<section id="pharmacokinetics-of-aztreonam" class="slide level2 smaller">
<h2>Pharmacokinetics of aztreonam</h2>
<table>
<colgroup>
<col style="width: 25%">
<col style="width: 74%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>IV only</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li>Aztreonam 0.28 L/kg, 38% protein binding</li>
<li>Avibactam 0.55 L/kg, 3% protein binding</li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½ 2-3 hours for both aztreonam and avibactam</p></li>
<li><p>Bile penetration: 115-400% aztroenam</p></li>
<li><p>CSF penetration: 3-52%</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Renal for both aztreonam and avibactam</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical adult doses</strong></td>
<td><ul>
<li><p>2 grams IV q6-8h</p></li>
<li><p>2 gm/0.67 gm (aztreonam-avibactam) IV load, then 1.5 gm/0.5 gm IV q6h</p></li>
<li><p>Infuse maintenance doses over 3 hours</p></li>
</ul></td>
</tr>
</tbody>
</table>
</section>
<section id="aztreonam-avibactam-adverse-effects" class="slide level2">
<h2>Aztreonam (avibactam) adverse effects</h2>
<p><br></p>
<ul>
<li><p>GI: nausea, vomiting, diarrhea, <em>C. difficile</em> infection, abdominal pain</p></li>
<li><p>Skin: rash, anaphylaxis</p></li>
<li><p>Liver: increased AST, ALT</p></li>
<li><p>Hematologic: anemia, thrombocytopenia</p></li>
<li><p>Confusion, dizziness</p></li>
</ul>
</section>
<section id="summary-pencillins" class="slide level2">
<h2>Summary-Pencillins</h2>
<p><br></p>
<ul>
<li>For select pathogens, still some of the rapidly killing agents</li>
<li>Short t½ = not the most practical agents</li>
<li>Time &gt; MIC pharmacodynamics, + short t½= activity maximized with prolonged infusions</li>
<li>Resistance, particularly ESBL, Amp-C have blunted broad-spectrum</li>
<li>New β-lactamase inhibitors can revive niche agents</li>
</ul>
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>
<p><br></p>
<div class="quarto-auto-generated-content">
<div class="footer footer-default">

</div>
</div>
<div class="hidden" aria-hidden="true">
<span class="glightbox-desc lightbox-desc-3">Sir Alexander Fleming in his laboratory, Pathé Films</span>
<span class="glightbox-desc lightbox-desc-8">Inhibition of transpeptidase (PBP)</span>
<span class="glightbox-desc lightbox-desc-9">Lysis of growing bacterial cells</span>
</div>
<div id="refs" class="references csl-bib-body" data-entry-spacing="0" role="list">
<div id="ref-abdul-aziz2024" class="csl-entry" role="listitem">
Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA 2024;332:638. <a href="https://doi.org/10.1001/jama.2024.9803">https://doi.org/10.1001/jama.2024.9803</a>.
</div>
<div id="ref-castells.etal_2019" class="csl-entry" role="listitem">
Castells M, Khan DA, Phillips EJ. Penicillin allergy. New England Journal of Medicine 2019;381:2338–51. <a href="https://doi.org/10.1056/NEJMra1807761">https://doi.org/10.1056/NEJMra1807761</a>.
</div>
<div id="ref-deoliveira2020" class="csl-entry" role="listitem">
De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clinical Microbiology Reviews 2020;33:e00181–19. <a href="https://doi.org/10.1128/CMR.00181-19">https://doi.org/10.1128/CMR.00181-19</a>.
</div>
<div id="ref-drusano2004" class="csl-entry" role="listitem">
Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ’bug and drug’. Nature Reviews Microbiology 2004;2:289–300. <a href="https://doi.org/10.1038/nrmicro862">https://doi.org/10.1038/nrmicro862</a>.
</div>
<div id="ref-dulhunty2024" class="csl-entry" role="listitem">
Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA 2024;332:629. <a href="https://doi.org/10.1001/jama.2024.9779">https://doi.org/10.1001/jama.2024.9779</a>.
</div>
<div id="ref-fleming_1929" class="csl-entry" role="listitem">
Fleming A. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2048009/">On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of b. influenzæ</a>. British Journal of Experimental Pathology 1929;10:226–36.
</div>
<div id="ref-harris2018" class="csl-entry" role="listitem">
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018;320:984–94. <a href="https://doi.org/10.1001/jama.2018.12163">https://doi.org/10.1001/jama.2018.12163</a>.
</div>
<div id="ref-huttner2020" class="csl-entry" role="listitem">
Huttner A, Bielicki J, Clements MN, Frimodt-Møller N, Muller AE, Paccaud J-P, et al. Oral amoxicillin and amoxicillin<span></span>clavulanic acid: Properties, indications and usage. Clinical Microbiology and Infection 2020;26:871–9. <a href="https://doi.org/10.1016/j.cmi.2019.11.028">https://doi.org/10.1016/j.cmi.2019.11.028</a>.
</div>
<div id="ref-noster2021" class="csl-entry" role="listitem">
Noster J, Thelen P, Hamprecht A. Detection of Multidrug-Resistant Enterobacterales<span></span>From ESBLs to Carbapenemases. Antibiotics 2021;10:1140. <a href="https://doi.org/10.3390/antibiotics10091140">https://doi.org/10.3390/antibiotics10091140</a>.
</div>
<div id="ref-pais2020" class="csl-entry" role="listitem">
Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, et al. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. The Journal of Antimicrobial Chemotherapy 2020;75:1228–36. <a href="https://doi.org/10.1093/jac/dkz563">https://doi.org/10.1093/jac/dkz563</a>.
</div>
<div id="ref-wanleenuwat2020" class="csl-entry" role="listitem">
Wanleenuwat P, Suntharampillai N, Iwanowski P. Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations. Seizure 2020;81:167–74. <a href="https://doi.org/10.1016/j.seizure.2020.08.012">https://doi.org/10.1016/j.seizure.2020.08.012</a>.
</div>
<div id="ref-wei2016" class="csl-entry" role="listitem">
Wei Y, Tang C, Sant V, Li S, Poloyac SM, Xie W. A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? Current Pharmacology Reports 2016;2:187–92. <a href="https://doi.org/10.1007/s40495-016-0062-1">https://doi.org/10.1007/s40495-016-0062-1</a>.
</div>
</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="Lecture1_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/plugin.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="Lecture1_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleChalkboard(event)\"><kbd>b</kbd> Toggle Chalkboard</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleNotesCanvas(event)\"><kbd>c</kbd> Toggle Notes Canvas</a></li>\n<li class=\"slide-tool-item\" data-item=\"6\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.downloadDrawings(event)\"><kbd>d</kbd> Download Drawings</a></li>\n<li class=\"slide-tool-item\" data-item=\"7\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'chalkboard': {"buttons":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'fast',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealChalkboard, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
        var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
        var mailtoRegex = new RegExp(/^mailto:/);
          var filterRegex = new RegExp('/' + window.location.host + '/');
        var isInternal = (href) => {
            return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
        }
        // Inspect non-navigation links and adorn them if external
     	var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool)');
        for (var i=0; i<links.length; i++) {
          const link = links[i];
          if (!isInternal(link.href)) {
            // undo the damage that might have been done by quarto-nav.js in the case of
            // links that we want to consider external
            if (link.dataset.originalHref !== undefined) {
              link.href = link.dataset.originalHref;
            }
          }
        }
      function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
        const config = {
          allowHTML: true,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start',
        };
        if (contentFn) {
          config.content = contentFn;
        }
        if (onTriggerFn) {
          config.onTrigger = onTriggerFn;
        }
        if (onUntriggerFn) {
          config.onUntrigger = onUntriggerFn;
        }
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          if (note) {
            return note.innerHTML;
          } else {
            return "";
          }
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    <script>var lightboxQuarto = GLightbox({"selector":".lightbox","closeEffect":"zoom","openEffect":"zoom","loop":false,"descPosition":"bottom"});
    window.onload = () => {
      lightboxQuarto.on('slide_before_load', (data) => {
        const { slideIndex, slideNode, slideConfig, player, trigger } = data;
        const href = trigger.getAttribute('href');
        if (href !== null) {
          const imgEl = window.document.querySelector(`a[href="${href}"] img`);
          if (imgEl !== null) {
            const srcAttr = imgEl.getAttribute("src");
            if (srcAttr && srcAttr.startsWith("data:")) {
              slideConfig.href = srcAttr;
            }
          }
        } 
      });

      lightboxQuarto.on('slide_after_load', (data) => {
        const { slideIndex, slideNode, slideConfig, player, trigger } = data;
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(slideNode);
        }
      });

    };
              </script>
    

</body></html>